[Bilateral subthalamic nucleus deep-brain stimulation (STN-DBS) in Parkinson's disease: initial experience in Cruces Hospital].
BACKGROUND
Clinical outcomes of Parkinson's disease patients treated for 12 months with STN-DBS were analyzed. PATIENTS ADN METHODS: Twelve patients were selected using the CAPSIT protocol criteria and placement of electrodes in the appropriate target was performed according to results of fusion image techniques and intraoperative microrecording.


RESULTS
A reduction in motor UPDRS (44 %) and activities of daily living (58 %) scores during <<off>> phases were observed. <<On>> time with dyskinesias was reduced (86 %), while severe dyskinesias disappeared. Levodopa dosage was also lowered (44 %). Patients and caregivers showed a clear-cut benefit on quality of life (58 % and 61 % respectively). No cognitive deterioration was observed and morbidity was in the same range as that published by other teams.


CONCLUSIONS
Bilateral STN-DBS is an effective symptomatic therapy for complicated Parkinsońs disease patients. It improves the quality of life of patients and their caregivers and allows a reduction of levodopa dosage.
Unidad de Cirugía de Movimientos Anormales, Servicio de Neurología Hospital de Cruces, Bilbao, Sapin. elezcano@hcr.osakidetza.net
E
E
Lezcano
J C
JC
Gómez
I
I
Lambarri
G
G
Bilbao
I
I
Pomposo
O
O
Rodríguez
R
R
Villoria
J J
JJ
Zarranz
P
P
Madoz
J
J
Garibi
D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D004599:Electric Stimulation Therapy / Q000295:instrumentation*; D005260:Female; D005500:Follow-Up Studies; D007839:Functional Laterality / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy*; D011788:Quality of Life; D020531:Subthalamic Nucleus / Q000503:physiopathology*; D016896:Treatment Outcome
D000978:Antiparkinson Agents